Sun Pharma’s $13bn Organon bid: funding, debt, fit

The binding offer that could reshape Sun Pharma

Sun Pharmaceutical Industries has submitted a binding all-cash offer of nearly $13 billion to acquire US-based Organon & Co, according to people familiar with the matter. If completed, it would be among the largest overseas acquisitions attempted by an Indian pharmaceutical company. The bid fits chairman Dilip Shanghvi’s stated push for Indian drugmakers to build the next phase of growth through innovative research while protecting their generics base. Sun is India’s largest drug company by revenue and also the most valuable listed player in the sector. The proposed deal has become a key talking point because Organon’s equity value is far smaller than the headline transaction value, highlighting how debt changes the economics of the acquisition.

Who Sun Pharma is up against

Sun Pharma is reported to be competing with Swedish buyout firm EQT and Germany’s Gruenthal for Organon. Gruenthal is described as a specialist in pain management. EQT and Gruenthal declined to comment in the reports cited. Sun Pharma and Organon also did not respond to queries. Competitive tension matters here because the asset is being marketed and tracked closely, and bidders typically need to show certainty of funds and clarity on refinancing.

How the financing is structured

Sun’s final offer is described as fully financed by three global banks, JP Morgan, MUFG and Citi, to the tune of $12 billion. JP Morgan is also acting as Sun’s adviser. Reports indicate Sun’s financing plan is predominantly aimed at taking on Organon’s debt, which would likely need refinancing as part of any transaction. Separately, Sun also has about $1.2 billion of net cash on its balance sheet, which it plans to use to buy the equity of the target. The valuation is described as linked to the equity value plus a premium, along with the debt assumed or refinanced.

Why Organon is attractive to strategic buyers

Organon is a women’s health focused company that was spun off from MSD (Merck Sharp & Dohme) in 2021. Reports describe suitor interest in Organon’s women’s health prospects across areas such as breast cancer, contraception, osteoporosis and menopause, and also in its biosimilars business. BNP Paribas analyst Navann Ty said Organon’s longer-term positioning remains strong as women’s health growth rebounds and biosimilars become a more meaningful growth driver with recent portfolio expansion. The analyst also pointed to VTAMA, described as a skin medicine, as a solid asset.

The debt issue at the heart of the deal

Any buyer of Organon will have to address the debt it inherited from MSD. Organon ended 2025 with $1.64 billion in debt. The company guided for 2026 revenue of $1.1-$1.3 billion, versus $1.4 billion reported for 2025. Reports also highlighted Organon’s leveraged balance sheet and muted growth expectations as negatives that have been temporarily overshadowed by buyout speculation. For Sun Pharma, the challenge is not only funding the transaction but also managing leverage and integration across a multi-therapy global portfolio.

What Sun could gain operationally

If Sun wins, the plan is to merge NYSE-listed Organon with Sun Pharma. Reports specify that Organon’s shareholders will not receive any Sun Pharma shares, reinforcing the all-cash nature of the proposal. The strategic logic discussed in the reports centres on adding a global women’s health portfolio and US front-end operations. That could complement Sun’s existing presence in specialty and generics and broaden its commercial footprint in a key regulated market.

Market reaction: Organon rallies, Sun slips

Organon’s stock has surged on deal speculation. One report said the shares have zoomed nearly 52% in the past month as buyout buzz intensified. Earlier, the stock was down 19.06% after a brief spurt in January when news of Sun’s interest became public. Another report cited a roughly 29% rally after an April 10 story about a final offer, while deal-focused coverage also referenced a roughly 28% jump on the headlines. On the Indian side, Sun Pharma shares fell nearly 4% in morning trade in Mumbai after reports of a binding offer, with one cited trade at ₹1,653.50, down 3.70%.

Sun Pharma’s scale and recent financial context

Sun Pharma closed one Thursday with a market valuation of ₹4.03 lakh crore (about $12.8 billion). In FY26, Sun Pharma reported sales of ₹52,000 crore (₹520 billion), with the US and India contributing almost an equal share of 31%-33%, while the rest was split among other markets and APIs. In a separate quarterly reference from Q3 FY26 coverage, Sun reported a 16% net profit increase to ₹3,368 crore (₹33.68 billion) and 15% higher sales of ₹15,469 crore (₹154.69 billion). Shanghvi has said the company would look at acquisitions only if they strengthen long-term strategic capability, while staying disciplined and avoiding dilution of focus on the existing business.

Key numbers at a glance

Why this matters for India’s pharma playbook

The reported transaction sits at the intersection of two pressures visible across the sector: pricing pressure in generics and the strategic pull toward branded, specialty, and innovation-led products. The bid’s structure, where funding is largely framed around debt refinancing and Sun’s own cash is earmarked for equity, underlines how the liabilities of the target shape enterprise value. The market’s immediate response, Organon’s sharp rise and Sun’s decline, reflects both deal optimism for the target and concern about leverage and integration risk for the acquirer. The next milestones, if the process continues, will hinge on bidder selection, debt refinancing terms, and any formal disclosures around material developments.

Conclusion

Sun Pharma’s reported binding offer for Organon signals a high-stakes attempt to add women’s health and biosimilars capabilities alongside a larger US commercial platform. The size of Organon’s debt and its relatively muted near-term revenue outlook remain central considerations. For now, both companies have not commented on the reports, while competitors have declined to comment. The market is likely to keep focusing on financing certainty, debt treatment, and any next steps on a definitive agreement.